ArticleMarine drugs2020
Chitosan Inhibits
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Myco-synthesized silver nanoparticles from Aspergillus niger AH1 as multifunctional anti-Helicobacter pylori agents: Antibacterial, antibiofilm, anti-urease, and antibiotic-synergistic activities.Folia microbiologica · 2026Article
- Urease inhibitors: current advances, therapeutic potentials, and clinical challenges.Future medicinal chemistry · 2026Review
- Curcumin-stabilized silver nanoparticles target the Helicobacter pylori-tumor interface in gastric cancer.Scientific reports · 2026Article
- Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026Review
- Chitosan-mediated nano-bioprocessing of Acacia seyal seed extract for enhanced antineoplastic, anti-Helicobacter pylori and antioxidant performance.Bioresources and bioprocessing · 2026Article
- Antibacterial hydrogels for skin infected wounds: frontier approaches as antibiotic alternatives therapy.Frontiers in cellular and infection microbiology · 2026Review
- New concepts of chitosan-based mucosal formulations for supporting control of the gastric pathogenFrontiers in microbiology · 2026Review
- ROS-induced allosteric modulation of NikR promotesVirulence · 2025Article
- Chitosan-based formulations for therapeutic applications. A recent overview.Journal of biomedical science · 2025Review
- Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025Review
- Anti-urease therapy: a targeted approach to mitigating antibiotic resistance in Helicobacter pylori while preserving the gut microflora.Gut pathogens · 2025Review
- Stimulus-responsive biomaterials for Helicobacter pylori eradication.Journal of advanced research · 2024Review
- The effect of three urease inhibitors onFrontiers in microbiology · 2024Article
- Amoxicillin-docosahexaenoic acid encapsulated chitosan-alginate nanoparticles as a delivery system with enhanced biocidal activities againstFrontiers in microbiology · 2023Article
- Application of biomaterials in the eradication ofFrontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
This study investigated the effects of shrimp chitosan with 95% degree of deacetylation (DD95) in combination with clinical antibiotics on the growth and urease production of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.